Currently, development of anticholinesterase drugs with improved potency, and drugs that act as dual acetylcholinesterase and amyloid-β aggregation inhibitors, are being sought to treat Alzheimer’s disease. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.